Polar Capital Holdings Plc Has $54.11 Million Stake in Enliven Therapeutics, Inc. $ELVN

Polar Capital Holdings Plc increased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 13.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,513,680 shares of the company’s stock after purchasing an additional 418,673 shares during the quarter. Polar Capital Holdings Plc owned about 5.92% of Enliven Therapeutics worth $54,111,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vestal Point Capital LP lifted its holdings in Enliven Therapeutics by 364.0% during the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after buying an additional 910,000 shares in the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at $9,990,000. Duquesne Family Office LLC raised its position in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares during the last quarter. Spruce Street Capital LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter worth $6,870,000. Finally, Marshall Wace LLP lifted its stake in shares of Enliven Therapeutics by 2,886.9% during the second quarter. Marshall Wace LLP now owns 333,333 shares of the company’s stock valued at $6,687,000 after acquiring an additional 322,173 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Up 0.4%

Shares of Enliven Therapeutics stock opened at $42.55 on Wednesday. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $48.53. The business has a fifty day simple moving average of $41.61 and a 200 day simple moving average of $31.08. The stock has a market cap of $2.59 billion, a PE ratio of -25.48 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Analysts expect that Enliven Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ELVN has been the topic of several recent research reports. Guggenheim began coverage on Enliven Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Stifel Nicolaus assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 9th. They set a “buy” rating and a $60.00 target price on the stock. Mizuho lifted their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $63.40.

Insider Buying and Selling at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. This trade represents a 16.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by corporate insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.